Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection.
We report here a series of 16 highly malignant diffuse large B-cell lymphomas of the oral cavity with unique immunohistologic features. Fifteen of these developed in human immunodeficiency virus-positive patients. All cases displayed morphologic features of diffuse large-cell lymphomas but strikingly differed from them in that they showed a minimal or absent expression of the leukocyte common antigen as well as of the B-cell antigen CD20. Instead, the tumor cells showed a constant reaction with the plasma cell characteristic antibody VS38c and a frequent reaction with the CD79a antibody. This, in conjunction with a variable expression of cytoplasmic Ig and a monoclonal rearrangement of the Ig heavy chain gene in all of the three tested cases confirmed the B-cell nature, the clonal origin, and the plasmacellular differentiation of these neoplasms. The majority of these tumors were negative for the BCL-6 protein, with the remaining cases showing only a partial and weak expression of this antigen. An association with the Epstein-Barr virus (EBV) was found in 9 of 15 tested cases showing abundant EBV-encoded nuclear RNA transcripts in the absence of EBNA-2. Five of the EBV-positive cases variably expressed LMP-1. We propose to name these tumors plasmablastic lymphomas, in accordance with their morphologic and immunohistologic features. Knowledge of this lymphoma entity is important to avoid confusion with nonlymphoid malignancies due to the lack of commonly used lymphoid markers.
Delecluse
H J
HJ
Institute of Pathology, Klinikum Benjamin Franklin, Free University of Berlin, Germany.
Anagnostopoulos
I
I
Dallenbach
F
F
Hummel
M
M
Marafioti
T
T
Schneider
U
U
Huhn
D
D
Schmidt-Westhausen
A
A
Reichart
P A
PA
Gross
U
U
Stein
H
H
D000328:Adult; D015703:Antigens, CD / Q000032:analysis; D018951:Antigens, CD20 / Q000032:analysis; D000951:Antigens, Neoplasm / Q000032:analysis; D001402:B-Lymphocytes / Q000473:pathology; D051925:CD79 Antigens; D002999:Clone Cells / Q000737:chemistry / Q000473:pathology; D005260:Female; D015326:Gene Rearrangement, B-Lymphocyte, Heavy Chain; D005803:Genes, Immunoglobulin; D005887:Gingival Neoplasms / Q000737:chemistry / Q000145:classification / Q000209:etiology / Q000473:pathology; D006566:Herpesviridae Infections / Q000150:complications; D004854:Herpesvirus 4, Human / Q000302:isolation & purification; D006801:Humans; D016130:Immunophenotyping; D016483:Lymphoma, AIDS-Related / Q000737:chemistry / Q000145:classification* / Q000473:pathology / Q000821:virology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000737:chemistry / Q000145:classification / Q000209:etiology* / Q000473:pathology / Q000821:virology; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000737:chemistry / Q000145:classification / Q000209:etiology* / Q000473:pathology / Q000821:virology; D015260:Neprilysin / Q000032:analysis; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000032:analysis; D011947:Receptors, Antigen, B-Cell / Q000032:analysis; D014412:Tumor Virus Infections / Q000150:complications; D014764:Viral Proteins / Q000032:analysis
D015703:Antigens, CD; D018951:Antigens, CD20; D000951:Antigens, Neoplasm; D051925:CD79 Antigens; C497881:CD79A protein, human; D019253:Proto-Oncogene Proteins c-bcl-2; D011947:Receptors, Antigen, B-Cell; D014764:Viral Proteins; D015260:Neprilysin